EUVIMEDEUVIMED entdecken
Crossref

A Non‐Metallic Nanozyme Ameliorates Pulmonary Hypertension Through Inhibiting ROS/TGF‐β1 Signaling

Ruxia Liu iD, Ting Zhou, Xinsheng Li, Quan Zou, Jiaojiao Yu, Jingjing Ye, Wenhui Wang, Yan Zhou, Shao-Kai Sun iD

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202401909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Ruxia Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, School of Medical Technology, Tianjin Medical University, Tianjin, 300203, China. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Reactive Oxygen Species, Hypertension, Pulmonary, Signal Transduction. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Scientific Research Project of Tianjin Education Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension (PH) is a life‐threatening cardiovascular disease with a lack of effective treatment options. Nanozymes, though promising for PH therapy, pose safety risks due to their metallic nature. Here, a non‐metallic nanozyme is reported for the treatment of monocrotaline (MCT)‐induced PH with a therapeutic mechanism involving the ROS/TGF‐β1 signaling. The synthesized melanin‐polyvinylpyrrolidone‐polyethylene glycol (MPP) nanoparticles showcase ultra‐small size, excellent water solubility, high biocompatibility, and remarkable antioxidant capacity. The MPP nanoparticles are capable of effectively eliminating ROS in isolated pulmonary artery smooth muscle cells (PASMCs) from PH rats, and significantly reduce PASMC proliferation and migration. In vivo results from a PH model demonstrate that MPP nanoparticles significantly increase pulmonary artery acceleration time, decrease wall thickening and PCNA expression in lung tissues, as evidenced by echocardiograpy, histology and immunoblot analysis. Additionally, MPP nanoparticles treatment improve running capacity, decrease Fulton index, and attenuate right ventricular fibrosis in MCT‐PH rats by using treadmill test, picrosirius red, and trichrome Masson staining. Further transcriptomic and biochemical analyses reveal that inhibiting ROS‐driven activation of TGF‐β1 in the PA is the mechanism by which MPP nanoparticles exert their therapeutic effect. This study provides a novel approach for treating PH with non‐metallic nanozymes based on a well‐understood mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor beta1Reactive Oxygen SpeciesHypertension, PulmonarySignal TransductionRats, Sprague-DawleyNanoparticlesPulmonary ArteryAnimalsRatsMaleCell ProliferationMyocytes, Smooth MusclePolyethylene GlycolsPovidoneMonocrotaline

Stichwörter der Autor:innen

ROSTGF‐β1 signalingmelaninnon‐metallic nanozymepulmonary hypertension

Substanzen

Transforming Growth Factor beta1Reactive Oxygen SpeciesPolyethylene GlycolsPovidoneMonocrotaline

Autor:innen und Institutionen

  • Department of Rehabilitation, School of Medical Technology, Tianjin Medical University, Tianjin, 300203, China.
  • School of Medical Imaging, Tianjin Medical University, Tianjin, 300203, China.
  • Department of CT, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi Province, 710068, China.
  • School of Medical Imaging, Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University, Tianjin, 300203, China.
  • Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
  • Trauma Treatment Center, Peking University People's Hospital, Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education, National Center for Trauma Medicine, Beijing, 100044, C…

ORCID-Profile: Ruxia Liu, Shao-Kai Sun

Förderung

  • Scientific Research Project of Tianjin Education Commission

Zitieren

APA

Liu, R., Zhou, T., Li, X., Zou, Q., Yu, J., Ye, J., Wang, W., Zhou, Y., & Sun, S. K. (2024). A Non‐Metallic Nanozyme Ameliorates Pulmonary Hypertension Through Inhibiting ROS/TGF‐β1 Signaling. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401909

Vancouver

Liu R, Zhou T, Li X, Zou Q, Yu J, Ye J, et al. A Non‐Metallic Nanozyme Ameliorates Pulmonary Hypertension Through Inhibiting ROS/TGF‐β1 Signaling. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401909

BibTeX
@article{Liu2024,
  author = {Liu, Ruxia and Zhou, Ting and Li, Xinsheng and Zou, Quan and Yu, Jiaojiao and Ye, Jingjing and Wang, Wenhui and Zhou, Yan and Sun, Shao-Kai},
  title = {A Non‐Metallic Nanozyme Ameliorates Pulmonary Hypertension Through Inhibiting ROS/TGF‐β1 Signaling},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202401909}
}
Kostenlos starten →